

DAFTAR PUSTAKA

- Aziz, M.F. 2009. Gynecological cancer in Indonesia. *Journal Gynecology Oncology*, 20(1): 8–10.
- Baay, M., Brouwer, A., Pauwels, P., Peeters, M. & Lardon, F. 2011. Tumor Cells and Tumor-Associated Macrophages : Secreted Proteins as Potential Targets for Therapy. *Clinical and Development Immunology*, 2011.
- Barry, J.A., Azizia, M.M. & Hardiman, P.J. 2014. Risk of endometrial , ovarian and breast cancer in women with polycystic ovary syndrome : a systematic review and meta-analysis. *Human Reproduction Update*, 20(5): 748–758.
- Będkowska, EW, Ewa Gacuta, Monika Zajkowska, Edyta Katarzyna Głażewska, Joanna Osada, Maciej Szmitkowski, Lech Chrostek², M.D. and S.Ł. 2017. Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers. *Journal of Ovarian Research*, 10(39): 1–10.
- Bodelon, C., Wentzensen, N., Schonfeld, S.J., Visvanathan, K., Hartge, P., Park, Y. & Pfeiffer, R.M. 2013. Hormonal risk factors and invasive epithelial ovarian cancer risk by parity. *British Journal of Cancer*, 109(3): 769–776.
- Chan, JK; Urban, R; Cheung, MK; Osann, K; Husain, A; Teng, NN; Kapp, DS; Berek, JS; Leiserowitz, GS. 2006. Ovarian cancer in younger vs older women: a population-based analysis. *British Journal of Cancer*, 95: 1314 – 1320.
- Chang LC; Huang CF; Lai MS; Shen LJ; Wu FL; Cheng WF. 2018. Prognostic factors in epithelial ovarian cancer: A population-based study. *PLoS One*, 13(3):e0194993.
- Chanmee, T., Ontong, P., Konno, K. & Itano, N. 2014. Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment. *Cancers* 6: 1670–1690.
- Charan, Jaykaran & Biswas, Tamoghna. 2013. How to calculate sample size for different study designs in medical research?. *Indian Journal Psychological Medicine*, 35(2): 121-6.
- Chauhan, S.C., Kumar, D. & Jaggi, M. 2009. Mucins in ovarian cancer diagnosis and therapy. *Journal of Ovarina Research*, 2(21): 1–9.

- Colvin, Emily K. 2014. Tumor-Associated Macrophages Contribute to Tumor Progression in Ovarian Cancer. *Frontier in Oncology*, 4: 137.
- Corney, David C , Chang-il Hwang, , Andres Matoso, Markus Vogt, Andrea Flesken- Nikitin, Andrew K. Godwin, Aparna A. Kamat, Anil K. Sood, Lora H. Ellenson, H. & Hermeking, and A.Y.N. 2010. Frequent downregulation of miR-34 family in human ovarian cancers. *Clinical Cancer Research*, 16(4): 1119.
- Corney, D.C. & Nikitin, A.Y. 2009. MicroRNA and ovarian cancer David. *Histology Histopathology*, 23(9): 1161–1169.
- Dahiya, N., Sherman-baust, C.A., Wang, T., Davidson, B. & Shih, I. 2008. MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer. *PlosOne*, 3(6) : e2436.
- Dahlan, S.M. 2013. Besar Sampel dan Cara Pengambilan Sampel. Jakarta: Salemba Medika.
- Davidson, B., Tropé, C.G. & Reich, R. 2014. Gynecologic Oncology The clinical and diagnostic role of microRNAs in ovarian carcinoma. *Gynecologic Oncology*, 133(3): 640–646.
- Desai, Arpita; Xu, Jingyao; Aysol, Kartik; Qi, Yunlong; Okoli, Chika; Hariprasad, Ravipati; Chinemerem, Ugorji; Gates, Candace; Redd, Avinash; Danner, Omar; Frankli, Geary; Ngozi, Anachebe; Cantuaria, Guilherme; Singh, Karan; Grizzle, William; Landen, Charles; Partridge, Edward E; Rice, Valerie Montgomery; Reddy, E Shyam P; Rao, Veena N. 2014. Epithelial ovarian cancer: An overview. *World Journal Translational Medicine*, 3(1): 1-8.
- Doubeni, C. A; Doubeni, Anna R. B; Myers, Allison E. 2016. Diagnosis and Management of Ovarian Cancer. *American Family Physician*, 93(11):937-944
- Essandoh, Kobina; Li, Yutian; Huo, Jiuzhou; and Fan, Guo-Chang. 2016. MiRNA-Mediated Macrophage Polarization and Its Potential Role in the Regulation of Inflammatory Response. *Shock*, 46(2): 122–131.
- Friebel, T.M; Domcheck, S.M dan Rebbect, T.R. 2014. Modifier of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis. *Journal of National Cancer Institute*, 106(6): dju091.

- Folsom, A.R; Anderson, J.P; Ros, J.A. 2004. Estrogen Replacement Therapy and Ovarian Cancer. *Epidemiology*, 15(1): 100-4.
- Gao, Z., Li, M., Zhang, L. & Zhao, Q. 2016. Serum microRNA-34c acts as a novel diagnostic biomarker in breast cancer patients. *International Journal Clinicology Exp*, 9(6): 6489–6494.
- Gates, Margaret A; Rosner, Bernard A; Hecht, Jonathan L; Tworoger, Shelley S. 2010. Risk Factors for by Histologic Subtype. *American Journal of Epidemiology*, 171(1): 45-53
- Gea, Imanuel. T; Loho, Maria. F; Wagey, Freddy. W. Gambaran jenis kanker ovarium di RSUP Prof. Dr. R.D. Kandou Manado periode Januari 2013 - Desember 2015. *Jurnal e-Clinic*, 4(2): 1-5.
- Gumusoglu, Ece and Gunel, Tuba, 2018. The Role of Circulating Biomarkers in the Early Diagnosis of Ovarian Cance: *Ovarian Cancer - From Pathogenesis to Treatment [serial online] [cited2019 March 5]. Available from: URL: <http://dx.doi.org/10.5772/intechopen.75484>*
- Gupta, M., Babic, A., Beck, A.H., Terry, K., Israel, B. & Medical, D. 2017. TNF- α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis? *Human Pathology*, 54: 82–91.
- Hanahan, D. & Weinberg, R.A. 2011. Review Hallmarks of Cancer : The Next Generation. *Cell*, 144(5): 646–674.
- He, Y., Zhang, M., Wu, X., Sun, X., Xu, T., He, Q. & Di, W. 2013. High MUC2 Expression in Ovarian Cancer Is Inversely Associated with the M1 / M2 Ratio of Tumor-Associated Macrophages and Patient Survival Time. *PlosOne*, 8(12): 1–14.
- Hermeking, H. 2009. The miR-34 family in cancer and apoptosis. *Cell Death and Differentiation*, 17(2): 193–199.
- Hirabayashi, Kenichi; Yasuda, Masanori; Kajiwara, Hiroshi; Itoh, Johbu; Miyazawa, Masaki; Hirasawa, Takeshi; Muramatsu, Thosinari; Murakami, Masaru; Mikami, Mikio; Osamura, RY. 2008. Alterations in Mucin Expression in Ovarian Mucinous Tumors: Immunohistochemical Analysis of MUC2, MUC5AC, MUC6, and CD10 Expression. *The Japan Society of*

Histochemistry and Cytochemistry, 41 (2): 15–21.

Hsu, H., Lai, M., Lee, J., Yen, M., Weng, T., Chen, W., Fang, J. & Chen, Y. 2017. Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling. *Scientific Reports*, (January): 1–14.

<http://www.mirtarbase.mbc.nctu.edu.tw>

<http://www.targetscan.org>

Hu, W., Li, X., Jiang, C.Z.Y.Y.J. & Wu, C. 2016. Tumor-associated macrophages in cancers. *Clinical Translational Oncology*, 18: 251–258.

Ii, R.L.G., Rodriguez, G.C., Whitaker, R.S., Dodge, R. & Voynow, J.A. 1998. Mucin Gene Expression in Ovarian Cancers. *Cancers Research* 58: 5546–5551.

Inaba, T., Sano, H., Kawahito, Y., Hla, T., Akita, K., Toda, M., Yamashina, I., Inoue, M. & Nakada, H. 2003. Induction of cyclooxygenase-2 in monocyte macrophage by mucins secreted from colon cancer cells. *PNAS*, 100(5): 2736–2741.

Jiang, Xiyi; Tang, Huijuan; Chen, Tianhui. 2018. Epidemiology of gynecologic cancers in China. *Journal Gynecology Oncology*, 29(1):e7.

Jr Kroeger, P.T. & Drapkin, R. 2017. Pathogenesis and heterogeneity of ovarian cancer. *Current opinion-obstetry gynecology*, 29(1): 27–34.

Karavitis, J., Hix, L.M., Shi, Y.H., Schultz, R.F. & Khazaie, K. 2012. Regulation of COX2 Expression in Mouse Mammary Tumor Cells Controls Bone Metastasis and PGE2- Induction of Regulatory T Cell Migration. *PlosOne*, 7(9): 1–11.

Karst, A.M. & Drapkin, R. E. 2010. Ovarian Cancer Pathogenesis : A Model in Evolution. *Journal of Oncology*, 2010: 1–13.

Kartika, A.I., Chasanah, S.N., Fitriawan, A.S., Tanjung, D.S., Trirahmanto, A., Pradjatmo, H., Aryandono, T., and Haryana, S.. 2018. MicroRNA-21 as a biomarker for ovarian cancer detection. *Indonesian Journal of Biotechnology*, 23(1), 2018, 35-39.

Katz, B. & Tropé, C.G. 2015. MicroRNAs in Ovarian Cancer . *Human Pathology*,

46(9): 1245–1256.

Kementerian Kesehatan RI, 2013. *Riset Kesehatan Dasar*. Kemenkes, Indonesia.

Kulbe, H., Hagemann, T., Szlosarek, P.W., Balkwill, F.R. & Wilson, J.L. 2005. The Inflammatory Cytokine Tumor Necrosis Factor- A Regulates Chemokine Receptor Expression on Ovarian Cancer Cells. *Cancers Research*, 65(22): 20355-10362.

Kurman, R.J and Shih, L.-M. 2011. The Origin and Pathogenesis of Epithelial Ovarian Cancer- a Proposed Unifying Theory Robert. *American Journal Surgical Pathology*, 34(3): 433–443.

Lassus, H., Laitinen, M.P.E., Anttonen, M., Heikinheimo, M., Aaltonen, L.A., Ritvos, O. & Butzow, R. 2001. Comparison of Serous and Mucinous Ovarian Carcinomas : Distinct Pattern of Allelic Loss at Distal 8p and Expression of Transcription Factor GATA-4. *Laboratory Investigation* 81(4): 517–526.

Li, Y., Hsieh, L., Tang, R., Liao, S. & Yeh, K. 2009. expression in the human colon cancer HT-29 cell line. *Cellular Immunology*, 256(1–2): 19–26.

Li, Y., Ren, X., He, Q., Xu, Y., Tang, X., Sun, Y., Zeng, M., Kang, T., Liu, N. & Ma, J. 2015. MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET. *Cell Death and Disease* 6: 1–10.

Livak, K.J & Schmittgen, T.D, 2001, Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and $2^{-\Delta\Delta CT}$ Method. *Methods*, 25: 402-408.

Llauradó, M., Majem, B., Altadill, T., Lanau, L., Castellví, J., Sánchez-iglesias, J.L., Cabrera, S., De, J., Díaz-feijoo, B., Pérez-benavente, A., Colás, E., Olivan, M., Doll, A., Alameda, F., Matias-guiu, X., Moreno-bueno, G., Carey, M.S., Maria, J., Campo, D., Gil-moreno, A., Reventós, J. & Rigau, M. 2014. Molecular and Cellular Endocrinology MicroRNAs as prognostic markers in ovarian cancer. *Molecular and Cellular Endocrinology*, 390: 73–84.

Marcheti, Claudia; Kristeleit, Rebecce; McCormack, Mary; Mould, Tim; Olaitan, Adeola; Widschwendter, Martin; Mcdonald, Nicola; Lederman, Jonathan A. 2017. Outcome of patients with advanced ovarian Cancer who do not undergo debulking surgery: A single institution retrospektif review. *gynecology Oncology*, 144(1): 57-60.

- Melin, A; Lundholm, C; Malki, N; Swanh, M.L; Sparen, P; Bergqvist, A. 2011. Endometriosis as a Prognostic Factor For Cancer Survival. *International Journal Cancer*, 129(4): 948-955.
- Mcguire, V., Hartge, P., Liao, L.M., Sinha, R., Bernstein, L., Canchola, A.J., Anderson, G.L., Stefanick, M.L. & Whittemore, A.S. 2017. Cancer Epidemiol Biomarker Prevention. *Cancer Epidemiol Biomarker Prevention*, 25(7): 1059–1063.
- Nadal, E., Chen, G., Gallegos, M., Lin, L., Ferrer-torres, D., Wang, Z., Lin, J., Reddy, R.M., Llatjos, R., Escobar, I., Moya, J., Chang, A.C., Cardenal, F., Capella, G. & Beer, D.G. 2014. Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early stage lung adenocarcinoma Ernest. *Clinical Cancer Research*, 19(24): 6842–6852.
- Nakamura, K., Sawada, K., Yoshimura, A., Kinose, Y., Nakatsuka, E. & Kimura, T. 2016. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. *Molecular Cancer* : 1–10.
- Noela, Fransisca & Nuryanto, Kartiwa H. 2016. Epidemiology Data of Ovarian Cancer in Dr. Cipto Mangunkusumo Hospital, Jakarta. *Obstetry and Gynecology Indonesia*, 4(2): 101-106.
- Ookawa, Keizou; Toshihiro, Kudo; Shu, Aizawa; Hiroshi, Saito; and Shigeki, T. 2002. Transcriptional Activation of the MUC2 Gene by p53 *. *Journal of Biological Chemistry* , 277(50): 48270–48275.
- Plagens-rotman, K., Chmaj-wierzchowska, K., Pięta, B. & Bojar, I. 2018. Modifiable lifestyle factors and ovarian cancer incidence in women. *Annals of Agricultural and Environmental Medicine*, 25(1): 36–40.
- Prat, J. 2015. FIGO ' s staging classification for cancer of the ovary , fallopian tube , and peritoneum : abridged republication. *Journal Gynecology Oncology*, 26(2): 87–89.
- Ravussin, Eric & Smith, Steven R. 2016. Role of the Adipocyte in Metabolism and Endocrine Function. *Endocrinology: Adult and Pediatric (Seventh Edition)* [Serial online] [Cited 2019 March 5]. Available from: URL: <https://doi.org/10.1016/B978-0-323-18907-1.00036-6>
- Razi, S., Ghoncheh, M., Mohammadian-hafshejani, A. & Aziznejhad, H. 2016. The incidence and mortality of ovarian cancer and their relationship with the

Human Development Index in Asia. *e Cancer Medical science*, 10(628) : 1–11.

Schmid, Michael. C and A. Varner, J udith. 2010. Myeloid Cell in the Tumor Microenvironment: Modulation Tumor Angiogenesis and Tumor Inflammation. *Journal of Oncology*, 2010: 1-10.

Serkies, K., Sinacki, M. & Jassem, J. 2013. The role of hormonal factors and endocrine therapy in ovarian cancer. *Onkologia*, 17(1): 14–19.

Singh, A.P., Senapati, S., Ponnusamy, M.P., Jain, M., Lele, S.M., Davis, J.S. & Remmenga, S. 2008. Clinical potential of mucins in diagnosis , prognosis , and therapy of ovarian cancer. *Lancet Oncology*, 9(11): 1076–1085.

Szlosarek, P.W., Grimshaw, M.J., Kulbe, H., Wilson, J.L., Wilbanks, G.D., Burke, F. & Balkwill, F.R. 2006. Expression and regulation of tumor necrosis factor A in normal and malignant ovarian epithelium. *Cancer Research*, 5(2): 382–391.

Tjindarbumi, D. & Mangunkusumo, R. 2002. Cancer in Indonesia , Present and Future. *Jpn Journal Clinicology Oncology*, 32(1): 5–7.

Torre, Lindsey A; Trabert, Britton; Carol. E; Miller, Kimberly. D; Samimi, Goli; Runowicz, Carolyn. D; Gaudet, Mia M; Jemal, Ahmedin; Siegel, Rebecca L. 2018. Ovarian Cancer Statistics, 2018. *Cancer Journal for Clinician*, 68:284–296.

Tung, S., Huang, W., Hsu, F., Yang, Z., Jang, T., Chang, J., Chuang, C., Lai, C. & Wang, L. 2017. miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway. *Oncogenesis*, 6(5): 1-13.

Vicus, Danielle; Finch, Amy; Rosen, Barry; Fan, Isabel; Bradley, Linda; Cass, Ilana; Sun, Ping; Karlan, Beth; McLaughlin, John; Narod, Steven A. 2010. Risk Factor for Carcinoma of The Fallopian Tube in Women with and without a Germline BRCA Mutation. *Gynecology Oncology*, 118(2):155-159.

Yu, Z., Kim, J., He, L., Creighton, C.J., Gunaratne, P.H. & Shannon, M. 2018. Functional Analysis of miR-34c as a Putative Tumor Suppressor in High-Grade Serous Ovarian Cancer 1. *Biology Of Reproduction*, 91(5):113, 1–12.

- Webb, P.M., Leader, G., Jordan, S.J., Head, T., Causes, C, 2016. Best Practice and Research Clinical Obstetrics and Gynecology Epidemiology of Epithelial Ovarian Cancer. *Research Clinical Obstetry Gynecology*, 1-12.
- Zeng, Z., Chen, X., Zhu, D., Luo, Z. & Yang, M. 2017. Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer. *Yonsei Medical Journal*, 58(4): 697–702.
- Zhang, M., He, Y., Sun, X., Li, Q., Wang, W., Zhao, A. & Di, W. 2014. A high M1 / M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. *Journal of Ovarian Research*, 7(19) : 1–16.
- Zhang, S., Lu, Z., Unruh, A.K., Ivan, C., Baggerly, K.A., Calin, G.A., Li, Z., Jr, R.C.B. & Le, X. 2015. Clinically Relevant microRNAs in Ovarian Cancer. *Molecular Cancer Research* 13:393-401.
- Zhang, Y. & Chen, Q. 2017. Relationship Between Matrix Metalloproteinases And The Occurrence And Development Of Ovarian Cancer. *Brazilian Journal of Medical and Biological Research*, 50: 6–13.
- Zhao, K., Cheng, J., Chen, B., Liu, Q., Xu, D. & Zhang, Y. 2017. Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer. *Journal of Thoracic Disease*, 9(10): 3735–3746.
- Zhou, X., Chen, H., Zhu, L., Hao, B., Zhang, W., Hua, J., Gu, H., Jin, W. & Zhang, G. 2016. Helicobacter pylori infection related long noncoding RNA (lncRNA) AF147447 inhibits gastric cancer proliferation and invasion by targeting MUC2 and up-regulating miR-34c. *Oncotarget*, 7(50): 82770–82782.
- Zohny, S.F., Fayed, S.T. & Ccl, M.-Á.C.C.L.Á. 2010. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. *Medical Oncology*, 7: 1246–1253.